Glucocorticoid therapy in connective tissue diseases;Glucocorticoidtherapie bei kollagenosen

Zeitschrift fur Rheumatologie

Volumn 64, Issue 3, 2005, Pages 162-169

  Unger, L ^a   Kayser, M ^a   Enderlein, M ^a   Manger, K ^b   Nusslein H ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Connective tissue diseases; Glucocorticoid effects; Organ manifestation; Side effects

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; GLUCOCORTICOID; HALOPERIDOL; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ARTERIOSCLEROSIS; ARTICLE; BONE NECROSIS; COMORBIDITY; CONNECTIVE TISSUE DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; KIDNEY FAILURE; LIVER DISEASE; MULTIPLE ORGAN FAILURE; MYOPATHY; NEPHRITIS; OSTEOPOROSIS; PLEURISY; PNEUMONIA; POLYMYOSITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TERATOGENICITY; TREATMENT INDICATION;

ANTI-INFLAMMATORY AGENTS; COLLAGEN DISEASES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 19944407947     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-005-0721-9     Document Type: Article

References (30)

1. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus (2004) Criteria for Steroid-Sparing Ability of Interventions in Systemic Lupus Erythematosus. Arthritis & Rheumatism 11:3427-3431
2. Aranow C, Ginzler EM (2000) Epidemiology of cardiovascular disease in systemic lupus erythematodes. Lupus 9:166-169
3. Bruce IN, Gladman DD, Urowitz MB (2000) Premature atherosclerosis in systemic lupus erythematodes. Rheum Dis Clin North Am 26:257-278
4. Buttgereit F, da Silva JAP, Baers M, Burmester G-R, Cutala M, Jacobs J Kirwan J, Köhler L, van Riel P, Vischer T, Bijlsma JWJ (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimes: current questions and tentative answers in rheumatology. Ann Rheum Dis 61:718-722
5. Buttgereit F, Straub RH, Wehling M, Burmester G-R (2004) Glucocorticoids in the Treatment of Rheumatic Diseases Arthritis& Rheumatism 50: 3408-3417
6. Buttgereit F, Wehling M, Burmester G-R (1998) A new hypothesis of modular glucocorticoid actions. Arthritis & Rheumatism 41:761-767
7. Chatham WW, Kimberly RP (2001) Treatment of lupus with corticosteroids. Lupus 10:140-147
8. Cheema GS, Quismorio FP (2000) Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 6:424-429
9. Denburg SD, Denburg JA (2003) Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 12:883-890
10. Derk CT, DeHoratius RJ (2004) Systemic lupus erythematosus and acute pancreatitis: a case series. Clin Rheumatol 23:147-151
11. Flanc RS, Matthew AR, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment of Diffuse Proliferative Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials. Am J Kidney Dis 43:197-208
12. Ginzler EM, Moldovan I (2004) Systemic lupus erythematosus trials: succeses and issues. Curr Opin Rheumatol 16:499-504
13. Glanz B, Slonim D, Urowitz MB (1997) Patterns of neuropsychological dysfunction in inactive systemic lupus erythematosus. Neuropsych Neuropsychol Behav Neurol 10:232-238
14. Hanly JG, McCurdy G, Fougere L, Douglas J, Thompson K (2004) Neuropsychiatric Events in Systemic Lupus Erythematosus: Attribution and Clinical Significance. J Rheumatol 31:2156-2162
15. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA (2000) Longitudinal analysis of bone mineral denity in pre-menopausal female systemic lupus erythematodes patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 39:389-392
16. Manger K, Kusus K, Forster C et al (2003) Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62:846-850
17. Manzi S (2000) Systemic lupus erythematodes: a model for atherogenesis? Rheumatology 39:353-359
18. Mavragani CP, Moutsopoulos HM (2003) Lupus nephritis: current issues. Ann Rheum Dis 62:795 798
19. Nived O, Sturfelt G, Liang MH, De Pablo P (2003) The ACR nomenclature for CNS lupus revisted. Lupus 12:872-87
20. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erthematosus: factors associated with referral for bone minaral densitiy studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13:436-441
21. Pryor BD, Bologna SG, Kahl LF (1996) Risk factor for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39:1475-1482
22. Schiffenbauer J, Hahn B, Weisman MH, Simon LS (2004) Biomarkers, Surrogate Markers, and Design of Clinical Trials of New Therapies for Systemic Lupus Erythematosus. Arthritis & Rheumatism 50:2415-2422
23. van Staa TP, Leufkens HGM, Cooper C (2002) The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis. Osteoporosis Int 13: 777-787
24. Sun SS, Huang WS, Chen JJH, Chang CP, Kao CH, Wang JJ (2004) Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematodes with brain involvement by Tc-99mHMPAO brain SPECT. Eur Radiol 14:1311-1315
25. Swaak AJG, van den Brink HG, Smeenk RJT, Manger K, Kalden JR, Tosi S et al (1999) Systemic lupus erythematosus: clinical features in patients with disease duration of over 10 years, first evaluation. Rheumatology 38:953-958
26. Trager J, Ward MW (2001) Mortality and causes of death in systemic lupus erythematodes. Curr Opin Rheumatol 13:345-351
27. Trysberg E, Tarkowski A (2004) Cerebral inflammation and degeneration in systemic lupus erythematosus. Curr Opin Rheumatol 16:527-533
28. Vasoo S, Thumboo J, Fong K-Y (2003) Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 12:630-632
29. Yuhara T, Takemura H, Akama T et al (1996) Predicting infection in hospitalized patients with systemic lupus erythematodes. Ontern Med 35:629-636
30. Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids Arthritis & Rheumatism 43:1801-1808